SR One Capital Management LP Invests $1.29 Billion in enGene Holdings Inc. $ENGN

SR One Capital Management LP bought a new position in shares of enGene Holdings Inc. (NASDAQ:ENGN) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 747,750 shares of the company’s stock, valued at approximately $1,293,607,000. enGene comprises about 0.1% of SR One Capital Management LP’s portfolio, making the stock its 15th biggest holding.

A number of other large investors have also added to or reduced their stakes in ENGN. Cresset Asset Management LLC acquired a new stake in enGene during the 2nd quarter valued at $36,000. Paloma Partners Management Co acquired a new position in shares of enGene in the second quarter valued at $38,000. Raymond James Financial Inc. increased its holdings in shares of enGene by 383.6% in the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock valued at $68,000 after purchasing an additional 7,932 shares during the last quarter. Jump Financial LLC bought a new position in shares of enGene in the fourth quarter valued at about $121,000. Finally, Millennium Management LLC lifted its stake in shares of enGene by 57.3% during the 3rd quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock worth $140,000 after buying an additional 7,472 shares during the last quarter. Institutional investors own 64.16% of the company’s stock.

enGene Price Performance

Shares of NASDAQ ENGN opened at $1.78 on Friday. The stock has a market capitalization of $119.24 million, a PE ratio of -0.82 and a beta of -0.28. The company has a debt-to-equity ratio of 0.10, a current ratio of 12.57 and a quick ratio of 12.57. The business has a fifty day moving average price of $1.80 and a two-hundred day moving average price of $4.76. enGene Holdings Inc. has a fifty-two week low of $1.40 and a fifty-two week high of $12.25.

enGene (NASDAQ:ENGN) last released its earnings results on Monday, June 15th. The company reported ($0.43) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.05. During the same period in the prior year, the company earned $0.51 EPS. As a group, equities analysts predict that enGene Holdings Inc. will post -1.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently commented on ENGN. Piper Sandler lowered shares of enGene from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $7.00 to $4.00 in a research note on Friday, May 8th. Raymond James Financial downgraded shares of enGene from a “strong-buy” rating to an “outperform” rating and set a $4.00 price objective for the company. in a research report on Friday, May 8th. UBS Group reduced their price objective on enGene from $9.00 to $2.00 and set a “neutral” rating for the company in a report on Thursday, May 14th. Morgan Stanley lowered enGene from an “equal weight” rating to an “underweight” rating and set a $3.00 target price on the stock. in a research note on Thursday, June 18th. Finally, Guggenheim cut enGene from a “buy” rating to a “neutral” rating in a report on Thursday, May 7th. Four research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $11.05.

enGene Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.